Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03426631 · ClinicalTrials.gov registry record · Phase 1

DAW1033B2 in Obstructive Sleep Apnea

A Phase 1 study of Obstructive Sleep Apnea (OSA), sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT03426631: Completed Phase 1 study of Obstructive Sleep Apnea (OSA), sponsored by Brigham and Women's Hospital.

NCT03426631 is a Phase 1 study of Obstructive Sleep Apnea (OSA) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 13 participants, below the 591-participant average among 12 other Obstructive Sleep Apnea (OSA) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03426631, a Phase 1 study of Obstructive Sleep Apnea (OSA), has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033B2 administered before sleep on OSA phenotype traits and OSA severity during sleep.

Primary Outcome

Based on previous studies the investigators anticipate that DAW1032B2 will reduce AHI more effectively in subjects with moderate sleep apnea, mildly obese (BMI\<32), Vpassive \> 50% of Veupnea (ventilation during eupneic ventilatory drive)

Interventions

  • DRUG Placebo oral capsule
  • DRUG DAW1033B2 oral capsule

Study Locations (1)

Massachusetts

  • Sleep Disorders Research Program Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2017-09-15
Est. Completion 2020-01-20
Phase Phase 1
Brigham and Women's Hospital

937 total trials

What the finished NCT03426631 record still lists

NCT03426631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 591-participant average among 12 other Obstructive Sleep Apnea (OSA) trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Obstructive Sleep Apnea (OSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.

NCT03426631 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03426631 about?

NCT03426631 is a clinical study titled "DAW1033B2 in Obstructive Sleep Apnea". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In th...

What is the current status of trial NCT03426631?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-09-15. Estimated completion is 2020-01-20.

What conditions does trial NCT03426631 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea (OSA).

What interventions are being tested in trial NCT03426631?

The interventions under investigation include: Placebo oral capsule (DRUG), DAW1033B2 oral capsule (DRUG).

Who is sponsoring clinical trial NCT03426631?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03426631 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea (OSA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03426631's enrollment target sits among peer trials

13 11th of 12 higher than 1 of 12 other Obstructive Sleep Apnea (OSA) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obstructive Sleep Apnea (OSA) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03426631, the US trial registry maintained by the National Library of Medicine. NCT03426631 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.